Preladenant

Preladenant (SCH 420814) is a drug developed by Schering-Plough which acts as a potent and selective antagonist at the adenosine A2A receptor. It is being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans.